Clinical and diagnostic assessment for therapeutic decisions in prostate cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 4, 2012, Pages 321-330

  Passoni, N M ^a   Di Trapani, E ^a   Suardi, N ^a   Gallina, A ^a   Abdollah, F ^a   Bianchi, M ^a   Picchio, M ^b,c   Giovacchini, G ^b   Messa, C ^c,d,e   Rigatti, P ^a   Montorsi, F ^a   Briganti, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Vita Salute San RaffaeleUniveristy ^*  (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

Author keywords

Diagnostic imaging; Prostatic neoplasms; Staging

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; BONE SCINTISCANNING; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING;

DECISION SUPPORT TECHNIQUES; DIAGNOSTIC IMAGING; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84869822276     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. NCCN Clinical Practice Guidelines In Oncology 2011: prostate cancer. [Accessed 2012 March 1; cited 2012 June 27]. Available at: http://www.nccn.org/ professionals/physician_gls/pdf/prostate.pdf.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. EurUrol 2011;59:61-71.
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. (Pubitemid 28445094)
5. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008;179:1354-60.
6. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. EurUrol 2010;58:687-700.
7. Choi WW, Williams SB, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Overuse of imaging for staging low risk prostate cancer. J Urol 2011;185:1645-9.
8. American Urological Association, Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update.
9. American Urological Association, Prostate-Specific Antigen Best Practice Statement: 2009 Update.
10. American College of Radiology ACR Appropriateness Criteria 2009, Pretreatment Staging Prostate Cancer.
11. Plawker MW, Fleisher JM, Vapnek EM, Macchia RJ. Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol 1997;158:1853-8. (Pubitemid 27433166)
12. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 2007;178:S14-9.
13. Pucar D, Sella T, Schoder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. CurrOpinUrol 2008;18:87-97. (Pubitemid 350307537)
14. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999;162:1337-40. (Pubitemid 29428575)
15. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer. Urology 1995;46:205-12.
16. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51. (Pubitemid 27208886)
17. Yu JB, Makarov DV, Sharma R, Peschel RE, Partin AW, Gross CP. Validation of the Partinnomogram for prostate cancer in a national sample. J Urol 2010;183:105-11.
18. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591-5.
19. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-8. (Pubitemid 34017254)
20. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101. (Pubitemid 46891611)
21. Karakiewicz PI, Bhojani N, Capitanio U, Reuther AM, Suardi N, Jeldres C et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 2008;180:898-902, discussion 902-3.
22. Bhojani N, Salomon L, Capitanio U, Suardi N, Shariat SF, Jeldres C et al. External validation of the updated Partin tables in a cohort of French and Italian men. Int J RadiatOncolBiolPhys 2009;73:347-52.
23. Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, Shariat SF et al. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. Eur J SurgOncol 2009;35:123-8.
24. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE et al. External validation is necessary in prediction research: a clinical example. J ClinEpidemiol 2003;56:826-32. (Pubitemid 37162656)
25. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J ClinEpidemiol 2003;56:441-7. (Pubitemid 36694096)
26. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. EurUrol 2006;49:820-6.
27. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844-9, discussion 1849.
28. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun FK, Schlom T, Perrotte P et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939-44, discussion 944.
29. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003;170:1203-8. (Pubitemid 37108113)
30. BaccalaJr A, Reuther AM,BiancoJr FJ, Scardino PT, KattanMW, Klein EA. Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multiinstitutional study of 6740 patients. Urology 2007;69:536-40. (Pubitemid 46428400)
31. Gallina A, Chun FK, Briganti A, Shariat SF, Montorsi F, Salonia A et al. Development and splitsample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. EurUrol 2007;52:98-105. (Pubitemid 46803017)
32. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostate cancer. Radiology 1989;170:609-15. (Pubitemid 19062568)
33. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography? BJU Int 2006,98:982-5. (Pubitemid 44536444)
34. Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Carcinoma of the prostate: value of transrectalsonography in detecting extension into the neurovascular bundle. AJR 1990;155:1015-9. (Pubitemid 20357001)
35. Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Capsular transgression of prostatic carcinoma: evaluation with transrectal US with pathologic correlation. Radiology 1991;178:791-5.
36. McSherry SA, Levy F, Schiebler ML, Keefe B, Dent GA, Mohler JL. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J Urol 1991;146:85-9.
37. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990;323:621-6. (Pubitemid 20280191)
38. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 1997;157:902-6. (Pubitemid 27066276)
39. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eschenbach AC, Geara FB. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 1999;85:1577-85. (Pubitemid 29152831)
40. Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331-6. (Pubitemid 17015632)
41. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. AJR 1987;149:315-8. (Pubitemid 17104987)
42. Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 1992;40:346-50.
43. Sciarra A, Salciccia S, Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. EurUrol 2008;54:485-8.
44. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ et al. Functional magnetic resonance imaging in prostate cancer. EurUrol 2009;55:801-14.
45. Kim B, Breau RH, Papadatos D, Fergusson D, Doucette S, Cagiannos I et al. Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5T for local staging of elevated risk prostate cancer. Can UrolAssoc J 2010;4:257-62.
46. Labanaris AP, Zugor V, Takriti S, Smiszek R, Engelhard K, Nutzel R et al. The role of conventional and functional endorectal magnetic resonance imaging in the decision of whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy. Scand J UrolNephrol 2009;43:25-31.
47. Sciarra A, Panebianco V, Salciccia S, Alfarone A, Gentilucci A, Lisi D et al. Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubicprostatectomy(RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP. J Sex Med 2009;6:1430-7.
48. Mattei A, Fuechsel FG, BhattaDhar N, Warncke SH, Thalmann GN, Krause T et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. EurUrol 2008;53:118-25. (Pubitemid 350166722)
49. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR et al. Pelvic lymph node dissection in prostate cancer. EurUrol 2009;55:1251-65.
50. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen Y et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology 2008;63:387-95.
51. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996;167:1503-7. (Pubitemid 26418741)
52. Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999;53:367-71. (Pubitemid 29063328)
53. Saksena MA, Kim JY, Harisinghani MG. Nodal staging in genitourinary cancers. Abdom Imaging 2006;31:644-51.
54. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U et al. Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. EurUrol 2011 [In press].
55. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR, CaPSURE Investigators. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 2006;176:1382-6. (Pubitemid 44316850)
56. Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. EurUrol 2006;49:1019-26.
57. Briganti A, Gallina A, Suardi N, Chun FK, Walz J, Heuer R et al. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int 2008;101:556-60.
58. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. EurUrol 2012;61:480-7.
59. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P et al. Kinetics of 11C-choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2003;31:317-24.
60. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2011;80:e50-6.
61. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5. (Pubitemid 39586006)
62. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al. (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. EurUrol 2008;54:392-401.
63. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al. [F(18)] fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 2010;46:449-55.
64. Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N et al. [(18)F]-fluorocholinepositronemission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010;106:639-43; discussion 644.
65. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009;50:1585-93.
66. Whitmore WF Jr. Natural history and staging of prostate cancer. UrolClin North Am 1984 May;11:205-20.
67. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. EurUrol 2010;57:551-8.
68. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976;121:431-4.
69. Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004,94:268-71. (Pubitemid 39120162)
70. Palvolgyi R, Daskivich TJ, Chamie K, Kwan L, Litwin MS. Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort. Urology 2011;77:1330-6.
71. Rudoni M, Antonini G, FavroM, BaroliA, Brambilla M, CardaniG et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995;22:207-11.
72. Cher ML, Bianco FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91. (Pubitemid 29480523)
73. Jacobson AF, Fogelman I. Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med 1998;25:1219-23. (Pubitemid 28446045)
74. Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d'Othée BJ et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J ClinOncol 2007;25:3281-7. (Pubitemid 47325613)
75. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J ClinOncol 2004;22:2942-53. (Pubitemid 41079914)
76. Sanal SM, Flickinger FW, Caudell MJ, Sherry RM. Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J ClinOncol 1994;12:1415-21. (Pubitemid 24206240)
77. Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). EurRadiol 2010;20:2973-82.
78. Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009;252:477-85.
79. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J RadiatOncolBiolPhys 2006 Jul;65:965-74.
80. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59. (Pubitemid 24145607)
81. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008;179:906-10.
82. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
83. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, Freedland SJ. et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171:2260-4. (Pubitemid 38625447)
84. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003;61:607-11. (Pubitemid 36294200)
85. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 2004;94:299-302. (Pubitemid 39120167)
86. Saleem MD, Sanders H, El Naser MA. Factors predicting cancer in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283-6. (Pubitemid 28093182)
87. Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997;70:995-9.
88. Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, Brambs HJ et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997;70:995-9.
89. Casalino DD, Remer EM, Arellano RS, Bishoff JT, Coursey CA, Dighe M et al. ACR Appropriateness Criteria® posttreatment follow-up of prostate cancer. J Am CollRadiol 2011;8:863-71.
90. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI et al. Suspected local recurrence after radical prostatectomy: endorectalcoilMRimaging. Radiology 2004;231: 379-85. (Pubitemid 38552892)
91. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997;168:379-85. (Pubitemid 27051968)
92. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190:1187-92.
93. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. EurRadiol 2009;19:761-9.
94. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. EurUrol 2008;54:589-600.
95. Picchio M, Giovannini E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. CurrOpinUrol 2011;21:230-6.
96. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. EurUrol 2011; 59:51-60.
97. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L et al. [11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26.
98. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L et al. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37;1106-16.90.